Abdominal multiphasic computed tomography (CT) or magnetic resonance imaging (MRI) is recommended in the setting of a rising serum AFP or following identification of a liver mass nodule ≥ 1 cm in the US, based on the guidelines of the American Association for the Study of Liver Diseases and Liver Imaging Reporting and Data System (Marrero et al., 2018), in which sensitivity for HCC is 87.5% and 83.1%, respectively (Tzartzeva et al., 2018). Here, AFP is linked to hepatocellular carcinoma.